Company news

Noxopharm Ltd. news in 2017

Noxopharm Ltd.'s news releases, calls and decks from 2017, newest first.

View company

EOY Guidance on 2018 NOX66 Clinical Development Strategy

December 21, 2017

Nyrada Inc Opens Capital Raise - Memorandum Released

November 30, 2017

NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model

November 28, 2017

Clarification of Incorrect Information

November 23, 2017

Promising Interim Clinical Data for NOX66

November 19, 2017

1st Patient treated in Lupin Study at St Vincents Hospital

November 15, 2017

UNSW collaboration confirms drug designed for stroke victims

November 2, 2017

Australian NOX66 - Radiotherapy Study Opens

September 26, 2017

Establishment of Nyrada Inc.

September 24, 2017

Positive Clinical Outcomes for NOX66 at ESMO Conference

September 11, 2017

Important Brain Cancer Findings for NOX66 Program

August 29, 2017

Reinstatement to Official Quotation

August 24, 2017

Noxopharm raises $5.5 million to advance clinical program

August 23, 2017

Suspension from Official Quotation

August 22, 2017

Noxopharm provides update on NOX66 Clinical Trial Program

July 5, 2017

Idronoxil data provides hope to treat secondary brain cancer

June 18, 2017

NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment

June 4, 2017

St Vincents Cancer Study to Commence-NOX66 and Radiotherapy

May 28, 2017

NOX makes strategic commitment to treatment of rare cancers

May 23, 2017

Market Guidance for Next Six Months

May 1, 2017

NOX Files Patent Application on Smart Idronoxil

April 9, 2017

NOX and Monash Uni Collaboration Receives Federal Grant

March 26, 2017

Noxopharm and UNSW combine on stroke project

March 15, 2017

NOX researching rare Abscopal Response

March 3, 2017

Brain Cancer Study Commences

January 31, 2017

First NOX66 Clinical Trial to Commence

January 30, 2017

Decks in 2017